Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis
Öz
Objective: Pulmonary large cell neuroendocrine carcinomas (LNECs) are not common but brain metastases are common in LNEC patients. Because of their rarity, there are no randomized controlled trials on optimal treatment. Generally available data are based on case reports and retrospective studies. For this reason, we retrospectively analyzed patients with LNEC that we followed up for brain metastases to contribute to the literature.
Methods: Between 2009 and 2020, 38 patients with brain metastases diagnosed with LNEC in our center were reviewed retrospectively.
Results: 38 patients were evaluated. The mean survival time was 5.17 months (95% confidence interval (CI) : 3.17-7.13). In multivariate analysis showed us that; shorter overal survival is associated with age (p=0.001), uncontrol of primary cancer (p=0.014), presence of metachronous metastases (p=0.003), poor Eastern Cooperative Oncology Group (ECOG) performance score (p=0.025), and high uric acid level (p=0.001) and high lactate dehydrogenase (LDH) levels (p=0.009).
Conclusion: LNECs are rare but aggressive cancers. LNECs often metastasize to the brain. According to our study, high LDH, high uric acid, poor ECOG performance score, ≥65 years, metachronous metastasis, uncontrolled primary tumor are associated poor prognosis. LDH, uric acid, age, presence of metachron metastasis, controbility of primary tumor can be used as easy and inexpensive biomarkers to determine the prognosis and in the follow-up and treatment of patients with LNECs with brain metastases as metastases seen of other cancers.
Anahtar Kelimeler
Kaynakça
- 1. Fasano M, Corte Della CM, Papaccio F, Ciardielle F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma from epidemiology to therapy. J Thoroac Oncol. 2015;10: 1133-1141.
- 2. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6): 529-53.
- 3. Battafarano RJ, Fernanadez FG, Ritter j, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc surg. 2005;130:166-172.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
19 Mart 2023
Gönderilme Tarihi
25 Ekim 2022
Kabul Tarihi
28 Şubat 2023
Yayımlandığı Sayı
Yıl 2023 Cilt: 50 Sayı: 1
APA
Kut, E., & Menekşe, S. (2023). Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. Dicle Medical Journal, 50(1), 30-36. https://doi.org/10.5798/dicletip.1266706
AMA
1.Kut E, Menekşe S. Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. diclemedj. 2023;50(1):30-36. doi:10.5798/dicletip.1266706
Chicago
Kut, Engin, ve Serkan Menekşe. 2023. “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”. Dicle Medical Journal 50 (1): 30-36. https://doi.org/10.5798/dicletip.1266706.
EndNote
Kut E, Menekşe S (01 Mart 2023) Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. Dicle Medical Journal 50 1 30–36.
IEEE
[1]E. Kut ve S. Menekşe, “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”, diclemedj, c. 50, sy 1, ss. 30–36, Mar. 2023, doi: 10.5798/dicletip.1266706.
ISNAD
Kut, Engin - Menekşe, Serkan. “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”. Dicle Medical Journal 50/1 (01 Mart 2023): 30-36. https://doi.org/10.5798/dicletip.1266706.
JAMA
1.Kut E, Menekşe S. Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. diclemedj. 2023;50:30–36.
MLA
Kut, Engin, ve Serkan Menekşe. “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”. Dicle Medical Journal, c. 50, sy 1, Mart 2023, ss. 30-36, doi:10.5798/dicletip.1266706.
Vancouver
1.Engin Kut, Serkan Menekşe. Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. diclemedj. 01 Mart 2023;50(1):30-6. doi:10.5798/dicletip.1266706